Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 22INDUSTRY 15NETWORK 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2

Conditions

Carcinoma, Non-Small-Cell Lung 13Lung Neoplasms 6Mesothelioma, Malignant 3Uterine Cervical Neoplasms 2Mesothelioma 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Unspecified Childhood Solid Tumor, Protocol Specific 1Solitary Fibrous Tumor, Pleural 1Sarcoma 1Ovarian Neoplasms 1Gestational Trophoblastic Disease 1Endometrial Neoplasms 1Colorectal Neoplasms 1Chondrosarcoma 1Carcinoma, Ovarian Epithelial 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Pemetrexed 2pembrolizumab 1Gemcitabine 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Mesothelioma × Pemetrexed × Clear all
NCT02784171 2024-12-10

Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

Canadian Cancer Trials Group

Phase 2/3 Completed
520 enrolled 16 charts 1 FDA
Other solid neoplasmThoracic

Mesothelioma

NCT00101283 2023-07-03

Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma

Eastern Cooperative Oncology Group

Phase 2 Completed
32 enrolled 8 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡